IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The Company’s development pipeline ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

Key Points ・Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or ...

Immuneering Corporation (NASDAQ:IMRX) released initial response data from the first five patients treated with IMM-1-104 in ...

IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The Company’s development pipeline ...

Immuneering Corp. (IMRX) announced positive initial response data from the first five patients treated with IMM-1-104 in combination ...

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

Spoon Labs’ most recent financing was in 2019, when it raised 45 billion won from investors including Naver, IMM Investment ...

MISO's Long Range Transmission Plan (LRTP) faces new challenges as it moves toward the approval of its $20 billion Tranche 2 ...

Germany on Saturday said there was an "urgent need" for measures to calm tensions in the Middle East as Israel's war on Hamas in Gaza threatened to spread to Lebanon.